Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.
暂无分享,去创建一个
M. Blaha | R. Blumenthal | S. Martin | Steven R. Jones | P. Toth | P. Kwiterovich | M. Elshazly | S. Jones
[1] P. Joshi,et al. Very Large Database of Lipids: Rationale and Design , 2013, Clinical cardiology.
[2] P. Joshi,et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. , 2013, Journal of the American College of Cardiology.
[3] C. M. D. de Cordova,et al. A new accurate, simple formula for LDL-cholesterol estimation based on directly measured blood lipids from a large cohort , 2013, Annals of clinical biochemistry.
[4] C. Naugler,et al. Fasting time and lipid levels in a community-based population: a cross-sectional study. , 2012, Archives of internal medicine.
[5] J. Gaziano. Should we fast before we measure our lipids? , 2012, Archives of internal medicine.
[6] J. Gaziano,et al. Cardiovascular risk assessment in the 21st century. , 2012, JAMA.
[7] E. Peterson,et al. The value of statistical analysis plans in observational research: defining high-quality research from the start. , 2012, JAMA.
[8] J. Ioannidis. The importance of potential studies that have not existed and registration of observational data sets. , 2012, JAMA.
[9] John Spertus,et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.
[10] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.
[11] D. Rader,et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.
[12] M. Taskinen,et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.
[13] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[14] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[15] Bin Chen,et al. A modified formula for calculating low-density lipoprotein cholesterol values , 2010, Lipids in Health and Disease.
[16] N. Keenan,et al. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. , 2009, JAMA.
[17] Robert Dufour,et al. Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .
[18] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[19] Samia Mora,et al. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events , 2008, Circulation.
[20] P. Tajik,et al. The impact of low serum triglyceride on LDL-cholesterol estimation. , 2008, Archives of Iranian medicine.
[21] C. Furberg,et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. , 2008, Journal of the American College of Cardiology.
[22] Curt D. Furberg,et al. Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.
[23] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .
[24] K. Kulkarni,et al. Cholesterol profile measurement by vertical auto profile method. , 2006, Clinics in laboratory medicine.
[25] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[26] R. Narang,et al. Low-density lipoprotein cholesterol estimation by a new formula in Indian population. , 2005, International journal of cardiology.
[27] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[28] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[29] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[30] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[31] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[32] P. Hopkins,et al. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia. , 1999, Clinical chemistry.
[33] K. Ryomoto,et al. Development of approximate formula for LDL-chol, LDL-apo B and LDL-chol/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. , 1998, Atherosclerosis.
[34] P. Bachorik,et al. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. , 1995, Clinical chemistry.
[35] A. Rao,et al. Calculation of low-density lipoprotein cholesterol with use of triglyceride/cholesterol ratios in lipoproteins compared with other calculation methods. , 1988, Clinical chemistry.
[36] R. Nicolosi,et al. Individual variation in serum cholesterol levels. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[37] E. DeLong,et al. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. , 1986 .
[38] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[39] R. Lees,et al. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. , 1967, The New England journal of medicine.